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Development of a novel radioiodinated dermorphin analog for mu 
opioid receptor studies 
 
Dermorphin is a naturally occurring opioid peptide that has been isolated from the skin of the frog 
Phylomedusa sauvagei.  It has been characterized as having high affinity and selectivity for the mu 
opioid receptor.  The goal of our study was to investigate novel analogs of dermorphin that could be 
radiolabeled and then evaluated as in vitro and in vivo probes for the mu opioid receptor.  Our group 
synthesized DAPP, a novel peptide and dermorphin derivative with the amino acid sequence H-Dmt-D-
Ala-Phe-Phe-NH2.  It has been radiolabeled with iodine and used in various experiments to determine 
its receptor binding characteristics.  Autoradiography studies were performed in order to define the 
profile of radioligand binding in mu, delta, and kappa opioid receptor types and to determine the 
degree of nonspecific binding and opioid receptor selectivity.  Autoradiography is the detection of 
radioisotopes on X-ray film.  For in vitro autoradiography, slide-mounted tissue sections of mouse brain 
were incubated with I-125 DAPP.  The tissue specimen itself was the source of the radiation, and the 
emissions of the isotopes formed a visible image upon development.  These studies indicated that I-125 
DAPP exhibits high levels of binding in the frontal cortex, striatum, thalamus, and superior and inferior 
colliculi, and low levels in the cerebellum.  The affinity of I-125 DAPP for mu opioid receptors was 
confirmed when labeling was not seen in the presence of a mu blocker (DAMGO); under the same 
conditions, I-125 DAPP was not prevented from binding by delta (DPDPE) or kappa (U69,593) blockers.  
Preliminary quantitative analysis of the distilled image by computerized densitometry suggests that we 
can achieve 80-90% specific binding with this compound.  As a prelude to in vivo studies, we 
determined the distribution coefficient (log D) for I-125 DAPP at pH 7.4.  This number is the ratio of 
the compound's concentration in the octanol phase to its concentration in the aqueous phase, and is an 
indication of the degree of lipophilicity of a compound.  The log D for I-125 DAPP was determined as 
2.99 ± 0.0117 (mean ± SD), using four consecutive measurements with a coefficient of variation 
(SD/mean x 100) of 0.39%.  This relatively high value indicates a more lipophilic compound, suggesting 
that that I-125 DAPP will successfully cross biological membranes.  An in vivo study was then conducted 
to determine the distribution of DAPP throughout the mouse body thirty minutes after injection.  The 
highest levels of uptake were found in the small intestine, while penetration in the brain was minimal.  
These results suggest that I-125 DAPP is a valuable compound for in vitro studies, particularly 
autoradiography, but has limited utility for in vivo studies in normal mice.  Nonetheless, I-125 DAPP 
may be suitable for in vivo targeting of certain cancers that over-express opioid receptors with respect 
to normal tissues. 
